CULLINAN THERAPEUTICS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CULLINAN THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $380.00K.
- CULLINAN THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2023-06-30 was $38.39M.
- CULLINAN THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2021-03-31 was $264.52M.
- CULLINAN THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2025 was $1.09M.
- CULLINAN THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2023 was $38.39M.
- CULLINAN THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2021 was $264.52M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-03-31 | $380.00K 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $1.09M 10-K · filed 2026-03-10 | |
| 2023-12-31 | $38.39M 10-K · filed 2025-02-27 | |
| 2023-06-30 | $38.39M 10-Q · filed 2024-11-07 | |
| 2021-12-31 | $264.52M 10-K · filed 2023-03-09 | |
| 2021-03-31 | $264.52M 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |